Research progress of asprosin in metabolic diseases and cardiovascular diseases
10.3760/cma.j.cn431274-20220308-00168
- VernacularTitle:白脂素在代谢性疾病及心血管疾病中的研究进展
- Author:
Kang WANG
1
;
Huiyu YANG
;
Lixia ZHI
Author Information
1. 山西医科大学第二医院心血管内科，太原 030001
- Keywords:
Metabolic diseases;
Cardiovascular diseases;
Asprosin
- From:
Journal of Chinese Physician
2022;24(11):1744-1747
- CountryChina
- Language:Chinese
-
Abstract:
Asprosin is a newly discovered fasting-induced glucogenic adipokine, which is involved in regulating appetite, glucose and fat metabolism and oxidative stress. Recently, it has been found that asprosin is related to metabolic diseases such as type 2 diabetes, obesity, nonalcoholic fatty liver, polycystic ovary syndrome, and cardiovascular diseases such as coronary heart disease and dilated cardiomyopathy, and plays an active role in heart protection. In this paper, the related research progress is summarized.
